ibusinesslines.com March 21, 2018

Arena Pharmaceuticals, Inc. (ARNA) has a Market value of 415.84 Million

19 June 2017, 05:56 | Jodi Jackson

Market Capitalization if basically the market value of the company's shares outstanding. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Arena Pharmaceuticals earned a coverage optimism score of 0.20 on Alpha One's scale. Wellington Grp Ltd Liability Partnership invested in 23.04M shares or 0.01% of the stock. The company had revenue of $6.60 million during the quarter, compared to analysts' expectations of $4.84 million.

Taking a broader look brokerage firms' analysts on the street with an expectant view have Arena Pharmaceutical (NASDAQ:ARNA) high price target of $5 and with a conservative view have low price target of $2. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -5.76% where SMA50 and SMA200 are -5.43% and -15.15% respectively. This represents a change from most recent open price of 0.21%. Senzar Asset owns 1.88 million shares.

Arena Pharmaceuticals (NASDAQ:ARNA) last released its quarterly earnings results on Tuesday, May 9th. The company reported the earnings of $-0.09/Share in the last quarter where the estimated EPS by analysts was $-0.07/share.

Arena Pharmaceuticals, Inc. (ARNA) revenue totaled $8.07 million down -90.55% from the previous quarter. Arena Pharmaceuticals had a negative return on equity of 265.98% and a negative net margin of 339.63%. Analysts are expecting EPS growth rates to be at 79.40% this quarter and EPS estimate for next year reflect -2.90% growth rate. Cantor Fitzgerald analyst W. Tanner anticipates that the biopharmaceutical company will post earnings per share of ($0.27) for the year. If you are viewing this story on another publication, it was stolen and republished in violation of US & worldwide trademark and copyright law. If you are reading this article on another site, it was stolen and reposted in violation of USA and worldwide trademark and copyright legislation.

A number of other equities research analysts also recently issued reports on the stock.

ILLEGAL ACTIVITY NOTICE: "Leerink Swann Initiates Coverage on Arena Pharmaceuticals, Inc". The 200 SMA is considered so critically important a trend indicator that the event of the 50-day SMA crossing to the downside of the 200-day SMA is referred to as a death cross, signaling a serious bear market in a stock, index or other investment. The stock now has a consensus rating of "Buy" and an average price target of $5.50. The lowest 12-month price target for the shares is $2.00, which would be an increase of about 59% of its current value.

Zacks offers analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. The rating was maintained by WallachBeth Capital on Wednesday, October 28 with "Buy". The stock presently has a consensus rating of "Buy" and an average price target of $38.00.

A number of large investors have recently added to or reduced their stakes in ARNA. Credit Suisse AG now owns 395,948 shares of the biopharmaceutical company's stock valued at $577,000 after buying an additional 103,167 shares during the period.

In other Arena Pharmaceuticals news, insider Amit Munshi bought 50,000 shares of the business's stock in a transaction dated Wednesday, April 26th. Metropolitan Life Insurance Co. NY now owns 172,165 shares of the biopharmaceutical company's stock valued at $251,000 after buying an additional 17,565 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Arena Pharmaceuticals by 102.0% in the first quarter. Bank of America Corp DE now owns 96,379 shares of the biopharmaceutical company's stock valued at $141,000 after buying an additional 48,667 shares in the last quarter.

Arena Pharmaceuticals, Inc. (ARNA) traded with the volume of 5.45 Million shares while its average 3 months volume is at 2410 shares.

Stock research firms now have a positive stance on shares of Keysight Technologies, Inc. Arena Pharmaceuticals, Inc. (ARNA) has made its way to a 12-month decline of -30.69%. The Firm is focused on developing small molecule drugs across a range of therapeutic areas.

Other News

Trending Now

Father's Day: Father a synonym for sacrifice!!
In this essay, Julie Hubschman talks about how losing her father has affected the way she views, and celebrates, Father's Day . Thomas said reflecting about his dad always helps him plan on how he can one day be a good dad, as well.

London vehicle hits pedestrians causing multiple casualties
The Muslim Council tweeted that worshippers were struck by a van as they were leaving prayers at the Finsbury Park mosque . Eight people were killed and more than 40 injured in the June 3 attack before the men were shot to death by authorities.

France's Macron to reshuffle govt after huge parliament win
He said the Socialist Party needs to change its ideas and its organization and that a "collective leadership" will replace him. With nearly all votes counted the LREM and its Modem allies won more than 300 seats in the 577-seat lower house.

Northam, Gillespie win gubernatorial nominations in Virginia primaries
Northam, a pediatric neurologist and Army veteran, emphasized his pragmatic approach and ability to work with Republicans . Far more voters seemed to turn out for the Democratic primary, perhaps twice as many, when the final votes are tallied.

HUDSON'S BAY CO (HBAYF) Stock Rating Reaffirmed by Royal Bank Of Canada
CIBC reduced their target price on shares of Hudson's Bay Co from C$13.00 to C$10.50 in a report on Monday, June 12th. Royal Bank Of Canada now has a C$9.00 price target on the stock, down from their previous price target of C$13.00.

Mosque Imam saves driver from angry mob after terror attack
The chairman of the Finsbury Park Mosque, Mohammed Kozbar, says the incident was a "cowardly attack" on worshippers. Witnesses said they saw people at the scene grab the man, pulling him from the van and started hitting him.

Fossil Group, Inc. (FOSL) Given Average Rating of "Hold" by Analysts
Over the last 5 years, Fossil Group, Inc . has averaged a -18.70% YoY EPS growth rate and a 3.50% revenue growth rate. BlackRock Investment Management LLC boosted its stake in shares of Fossil Group by 0.3% in the third quarter.